Compare IPDN & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPDN | PFSA |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.0K | 902.5K |
| IPO Year | 2012 | 2021 |
| Metric | IPDN | PFSA |
|---|---|---|
| Price | $0.60 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.1K | ★ 1.8M |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,054,219.00 | $100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.32 |
| 52 Week High | $7.70 | $45,495.00 |
| Indicator | IPDN | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 25.19 | 31.02 |
| Support Level | $0.33 | N/A |
| Resistance Level | $1.49 | $0.65 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 4.89 | 2.33 |
Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.